ClinicalTrials.gg
CompletedNCT05082233Updated Feb 20, 2024

Identify Effective Doses of SHR7280 Tablets in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART)

A Phase 2 interventional study of SHR7280 tablets in Female Subjects Undergoing COH in ART to Prevent Early Ovulation, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to female participants aged 20 Years to 39 Years. Per ClinicalTrials.gov, last updated 2024-02-20.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
85
Allocation
Not applicable
Ages
20 Years to 39 Years
Sex
Female
01

Study summary

This study is a multicentre, open-label phase II dose-finding clinical trial that will recruit approximately 120 female subjects undergoing COH for in vitro fertilization (IVF) or intracytoplasmic single sperm injection (ICSI). We set up three SHR7280 tablets dose groups of 300 mg BID, 200 mg BID, and 200 mg QD with 40 subjects in each group, besides, a group of 400mg bid is set as an alternative.

02

Conditions studied

  • Female Subjects Undergoing COH in ART to Prevent Early Ovulation
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 39 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Married infertile female subjects aged 20 to 39 years with indications for in vitro fertilization-embryo transfer (IVF-ET) or intracytoplasmic monosperm microinjection (ICSI) techniques.
  2. (BMI) of 18 to 28 kg/m2.
  3. Regular menstrual cycle (24 to 35 days) for the last 3 months prior to screening.
  4. Screening serum sex hormone levels must be performed on day 2 to 3 in the menstrual cycle and meet basal serum follicle stimulating hormone (FSH) \< 10 IU/L; LH, estradiol (E2), progesterone (P), prolactin (PRL), and total testosterone levels within the normal laboratory range, or the investigator considers the abnormality without clinical significance; 1.2 ng/mL \< anti-müllerian hormone (AMH) \< 4.0 ng/mL.
  5. Expected normal ovarian response.
  6. Clinical feasible and willingness of the subject to undergo fresh cycle transfer with one or two embryos at a time in the first IVF-ET cycle.
  7. Able and willing to provide a written .

Exclusion criteria

Exclusion Criteria:

  1. Subjects underwent 3 or more controlled ovarian stimulation cycles of IVF/ICSI-ET prior to screening without achieving clinical pregnancy.
  2. Previous IVF or ART failure due to sperm/fertilization problems and no improvement in related medical condition.
  3. Subjects had spontaneous abortion≥2 times.
  4. Subjects at high risk of OHSS, judged by the investigator according to the Golan classification (e.g., those with moderate to severe OHSS during previous superovulatory cycles, polycystic ovary syndrome (PCOS) [refer to the 2018 Chinese PCOS guidelines] [1], or with previous cancelled cycles due to OHSS).

    Note: The 2018 Chinese PCOS guideline specifies the diagnostic criteria as meeting 1 of the following 2 items: ① hyperandrogenic manifestations or irregular menstruation: scanty or amenorrhea menstruation or irregular uterine bleeding are required for the diagnosis. ②Other diseases that may cause hyperandrogenism or abnormal ovulation should be excluded.

  5. Subjects with low ovarian function meeting at least one of the following items: poor previous ovarian response (≤3 ovums obtained with previous conventional adequate Gn stimulation regimen); less than 7 follicles of 2-9 mm diameter (AFC) count visible on vaginal ultrasound in both ovaries; anti-mullerian hormone (AMH) \< 1.1 ng/mL.
  6. Any pregnancy that occurred within 3 months prior to screening date.
  7. Subjects with abnormal cervical findings within 6 months prior to screening (TCT).

    Note: Human papillomavirus (HPV) testing may be used as an adjunct in subjects with atypical squamous cells of undefined significance (ASC-US). Subjects may be included in the study if only the high-risk HPV strains test was negative.

  8. Unexplained abnormal vaginal bleeding.
  9. Persons who have donated blood or blood components within 1 month prior to screening, or have lost at least the equivalent of 200 mL of blood, or have received a blood transfusion within 2 months.
  10. Subjects had a serious infection, severe trauma or major surgical procedure within 6 months prior to screening.
  11. Use of clomiphene citrate, letrozole, gonadotropins (Gn), metformin, or oral within 1 month prior to receiving ovarian stimulation.
  12. Abnormal blood (ALT) and aspartate aminotransferase (AST) values on screening visit or ovarian stimulation day 1 visit.
  13. Positive serum beta-hCG test result on day 1 of screening visit or ovarian stimulation.
  14. Positive results for infectious diseases (including virus surface antigen, virus antibodies, antibodies, and syphilis spirochete antibodies).
  15. Subjects with clinically significant abnormalities of the uterus and ovaries judged by the investigator, (e.g., submucosal fibroids, interstitial fibroids larger than 3 cm or less than 3 cm but affecting the morphology of the uterine cavity, untreated endometrial polyps, uterine adhesions, uterine malformations, ASRM stage III-IV endometriosis).
  16. Any disease or condition that can affect the function of body systems and may affect the absorption, excessive accumulation, affect metabolism, or alter the excretion pattern of the study drug (e.g., chronic bowel disease, Crohn's disease, ulcerative colitis).
  17. Subjects with clinically significant systemic disease, endocrine or metabolic abnormalities.
  18. Previous or current thromboembolic disease.
  19. Subjects or their spouses with structural chromosomal abnormalities, or with known monogenic genetic disorders or serious diseases with genetic susceptibility requiring preimplantation genetic testing (PGT).
  20. History of tobacco or alcohol abuse within 3 months prior to screening: tobacco addiction (more than 5 cigarettes or equivalent per day); alcohol abuse (greater or equal to 14 units of alcohol per week: 1 unit = 360 mL of beer, or 25 mL of spirits 40% or more in strength, or 1 glass of wine, 180 mL).
  21. History of substance abuse, drug dependence.
  22. Allergy or allergy to two or more foods or drugs, including known history of allergy to the study drug or any component of the study drug.
  23. Subjects that have participated in a clinical trial of any drug or medical device within 3 months prior to screening, or are still within the follow-up period of a clinical study or within 5 half-lives of the trial drug (depends on the longer one) prior to screening
  24. History of malignant tumors of the ovaries, breast, uterus, hypothalamus, pituitary gland, etc.
  25. Subjects with serious mental disease or who are unable to understand the purpose and methods of this clinical trial.
  26. Any other reason deemed by the investigator to be unsuitable for participation in this study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    SHR7280 tablets

    Treatment group A: oral SHR7280 tablets; 300mg bid p.o.; Treatment group B: oral SHR7280 tablets; 200mg bid p.o.; Treatment group C: oral SHR7280 tablets; 200mg qd p.o.; Treatment group D: oral SHR7280 tablets; 400mg bid p.o.; as an alternative.

    Drug: SHR7280 tablets

Interventions

  • Treatment group A:SHR7280 tablets ; 300mg BID; Treatment group B:SHR7280 tablets ; 200mg BID; Treatment group C:SHR7280 tablets ; 200mg QD; Treatment group D:SHR7280 tablets ; 400mg BID;

06

What researchers measure

Primary outcomes

  1. Inhibition rate of early LH serge with different oral doses of SHR7280 tablets from the 1st day of study drug administration to the date of hCG injection

    Time frame: Through the whole period of oral administration of SHR7280, generally 5-7 days)

Secondary outcomes

  1. The proportion of embryos with 2 protoplasts in the cytoplasm 16-18 hours (h) after fertilization (2PN rates).

    Time frame: On embryo transfer day, 3 days after oocyte retrieval

  2. Quality embryo rates

    Time frame: On embryo transfer day, 3 days after oocyte retrieval.

  3. Clinical pregnancy rates.

    Time frame: On pregnancy test day

  4. Total dose of gonadotropin (Gn) administered and duration of gonadotropin treatment

    Time frame: Through the whole period of controlled ovarian stimulation, generally 9-11 days

  5. Adverse drug events

    Time frame: Through study completion, follow-up period may be up to 40 weeks if the patient gets a successful clinical pregnancy and a full term delivery

  6. Population PK endpoints: analysis of plasma SHR7280 concentration data, population pharmacokinetic modeling, and calculation of key pharmacokinetic parameters of SHR7280 in subjects

    Time frame: Blood samples were collected within 30 minutes before,, 1-3 hours after and 5-8 hours after the oral administration of SHR7280 in the morning on hCG injection day, generally the 9th day to the 11st day of the period of controlled ovarian stimulation

  7. PD endpoints: serum E2, luteinizing hormone (LH) and progesterone (P) concentrations at each time point

    Time frame: 30 minutes before the oral administration of SHR7280 every morning during SHR7280 treatment period

07

Study locations

1 site
  • Peking University Third Hospital
    Beijing, Beijing 100191, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Aug 2023, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2021
First posted
Oct 18, 2021
StartActual
Mar 6, 2022
Primary completionActual
Aug 3, 2023
CompletionActual
Aug 3, 2023
Last update
Feb 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05082233
Responsible party
Sponsor
First posted
Oct 18, 2021
Start date
Mar 6, 2022
Primary completion
Aug 3, 2023
Completion
Aug 3, 2023
Last update
Feb 20, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GnRH Antagonist SHR7280

Start the discussion